Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent
16-11-2021
GSK claims Amgen v Sanofi decision “threatens” innovation
29-04-2021
Amgen antibody patents ‘too broad’, says Fed Circuit
16-02-2021
Sundry Photography / Shutterstock.com
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen (filgrastim).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Pfizer, patent, cancer treatment
